Drugs / VPM1002
VPM1002
also known as
VPM1002BC · Mycobacterium bovis BCG ΔureC::hly Hm(R) · Mycobacterium bovis rBCGΔureC::hly · rBCG
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01113281 | Apr → Dec 2010 | tuberculosis | Serum Life Science Europe GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00749034 | Sep 2008 → Dec 2009 | tuberculosis | Serum Life Science Europe GmbH | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05539989 | Dec 2025 | HIV infectious disease, tuberculosis | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02371447 | Sep 2015 → Oct 2019 | urinary bladder cancer | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04630730 | Jun 2022 → Jun 2026 overdue | urinary bladder cancer | Swiss Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02391415 | Jun 2015 → Nov 2017 | tuberculosis | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01479972 | Nov 2011 → Nov 2012 | tuberculosis | Serum Life Science Europe GmbH | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03152903 | Dec 2017 → Dec 2023 | tuberculosis | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04351685 | Nov 2020 → Oct 2024 | tuberculosis | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04439045 | Jun 2020 → Sep 2021 | COVID-19 | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 3 | NCT04435379 | Jun 2020 → Oct 2021 | respiratory tract infectious disorder | Serum Life Science Europe GmbH | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04387409 Comparator | May 2020 → Apr 2021 | respiratory tract infectious disorder | Serum Life Science Europe GmbH | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VPM1002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04387409 ↗ |
| Known as | Mycobacterium bovis BCG ΔureC::hly Hm(R) | “received one intradermal dose of VPM1002 (Mycobacterium bovis BCG ΔureC::hly Hm(R)) or BCG” PMID 23290835 ↗ Jan 2013 |
| Known as | Mycobacterium bovis rBCGΔureC::hly | “Mycobacterium bovis rBCGΔureC::hly (VPM1002) vaccination” NCT05539989 ↗ |
| Known as | rBCG | “Intravesical recombinant BCG (rBCG: VPM1002BC) is applied weekly for three instillations followed by four cycles of neoadjuvant cisplatin/gemcitabine every 3 weeks.” PMID 37286312 ↗ Jun 2023 |
| Known as | VPM1002BC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02371447 ↗ |
| Modality | Vaccine | “a recombinant BCG vaccine candidate” PMID 23290835 ↗ Jan 2013 |
| Route | Other | “administered intradermally” NCT04351685 ↗ |